Anbio Biotechnology (NASDAQ:NNNN) Short Interest Update

Anbio Biotechnology (NASDAQ:NNNN) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 31,583 shares, a decline of 64.6% from the June 30th total of 89,295 shares. Based on an average daily volume of 42,616 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.0% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.

Anbio Biotechnology Price Performance

NNNN traded down $0.20 during trading hours on Monday, hitting $9.70. 4,199 shares of the stock were exchanged, compared to its average volume of 43,938. The stock has a 50-day simple moving average of $18.43. Anbio Biotechnology has a 12 month low of $8.30 and a 12 month high of $54.95.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.